肝癌合并门静脉癌栓

Hepatocellular carcinoma with portal vein thrombus

以上为机器翻译结果，快速获取精准的人工翻译结果，建议选择有道人工翻译

1
portal vein tumor thrombus
1 资料与办法原发性肝癌合并门静脉癌栓(portal vein tumor thrombus,PVTT)是原发性肝癌晚期主要表达，预后很差，发生率约为62.2百分之百～90.0百分之百[1]，造成患者在短...
2
PVTT
1 资料与办法原发性肝癌合并门静脉癌栓(portal vein tumor thrombus,PVTT)是原发性肝癌晚期主要表达，预后很差，发生率约为62.2百分之百～90.0百分之百[1]，造成患者在短...

1
放射介入栓塞化疗对肝癌合并门静脉癌栓治疗的疗效观察。
Transcatheter arterial chemoembolization therapy in the treatment of hepatocellular carcinoma with tumor thrombus of portal vein.
2
目的探讨肝癌合并门静脉癌栓的手术疗效，评价术中门静脉癌栓取出术和术后辅助肝动脉栓塞化疗对提高肝癌术后生存率的影响。
Objective To explore the value of removing portal vein tumor thrombus (PVTT) and TACE in improving the outcome of resection for primary liver cancer with PVTT.
3
结果：有28例发现肝脏灌注异常影像表现（21.1%，28/133），以原发性肝细胞癌为多见（22.5%，20/89），尤其是合并门静脉癌栓的肝癌病例（46.2%，12/26）。
Results:28 cases were found to have hepatic perfusion disorders(21.1%, 28/133). The common cause was HCC(22.5%, 20/89), especially HCC with portal vein tumor thrombus(46.2%, 12/26).

点击反馈